Friday, 10 February 2017

Immunomedics in $2 billion licensing deal with Seattle Genetics

(Reuters) - Immunomedics Inc said it entered into a licensing deal for its cancer treatment with Seattle Genetics Inc for a potential payment of up to about $2 billion.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)